493 related articles for article (PubMed ID: 30702009)
1. Are antibodies directed against amyloid-β (Aβ) oligomers the last call for the Aβ hypothesis of Alzheimer's disease?
Panza F; Lozupone M; Dibello V; Greco A; Daniele A; Seripa D; Logroscino G; Imbimbo BP
Immunotherapy; 2019 Jan; 11(1):3-6. PubMed ID: 30702009
[No Abstract] [Full Text] [Related]
2. Amyloid beta peptide immunotherapy in Alzheimer disease.
Delrieu J; Ousset PJ; Voisin T; Vellas B
Rev Neurol (Paris); 2014 Dec; 170(12):739-48. PubMed ID: 25459121
[TBL] [Abstract][Full Text] [Related]
3. SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA).
Pradier L; Blanchard-Brégeon V; Bohme A; Debeir T; Menager J; Benoit P; Barneoud P; Taupin V; Bertrand P; Dugay P; Cameron B; Shi Y; Naimi S; Duchesne M; Gagnaire M; Weeden T; Travaline T; Reczek D; Khiroug L; Slaoui M; Brunel P; Fukuyama H; Ravetch J; Canton T; Cohen C
Alzheimers Res Ther; 2018 Nov; 10(1):117. PubMed ID: 30486882
[TBL] [Abstract][Full Text] [Related]
4. Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?
Panza F; Logroscino G; Imbimbo BP; Solfrizzi V
Curr Opin Psychiatry; 2014 Mar; 27(2):128-37. PubMed ID: 24445401
[TBL] [Abstract][Full Text] [Related]
5. Treatments for Alzheimer's disease emerge.
Selkoe DJ
Science; 2021 Aug; 373(6555):624-626. PubMed ID: 34353940
[No Abstract] [Full Text] [Related]
6. Alzheimer's therapy: a BACE in the hand?
Nat Med; 2011 Aug; 17(8):932-3. PubMed ID: 21818090
[No Abstract] [Full Text] [Related]
7. Structural aspects of Alzheimer's disease immunotherapy targeted against amyloid-beta peptide.
Cehlar O; Skrabana R; Revajova V; Novak M
Bratisl Lek Listy; 2018; 119(4):201-204. PubMed ID: 29663816
[TBL] [Abstract][Full Text] [Related]
8. A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice.
Neumann U; Rueeger H; Machauer R; Veenstra SJ; Lueoend RM; Tintelnot-Blomley M; Laue G; Beltz K; Vogg B; Schmid P; Frieauff W; Shimshek DR; Staufenbiel M; Jacobson LH
Mol Neurodegener; 2015 Sep; 10():44. PubMed ID: 26336937
[TBL] [Abstract][Full Text] [Related]
9. Conformation-specific antibodies to target amyloid β oligomers and their application to immunotherapy for Alzheimer's disease.
Murakami K
Biosci Biotechnol Biochem; 2014; 78(8):1293-305. PubMed ID: 25130729
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy for Alzheimer's disease.
Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q
Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646
[TBL] [Abstract][Full Text] [Related]
12. Targeting beta-amyloid pathology in Alzheimer's disease with Abeta immunotherapy.
Nitsch RM; Hock C
Neurotherapeutics; 2008 Jul; 5(3):415-20. PubMed ID: 18625453
[TBL] [Abstract][Full Text] [Related]
13. A Novel scFv Anti-Aβ Antibody Reduces Pathological Impairments in APP/PS1 Transgenic Mice via Modulation of Inflammatory Cytokines and Aβ-related Enzymes.
Hu M; Zhang J; Yang J; Cao Y; Qi J
J Mol Neurosci; 2018 Sep; 66(1):1-9. PubMed ID: 30062438
[TBL] [Abstract][Full Text] [Related]
14. Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward.
Panza F; Solfrizzi V; Imbimbo BP; Tortelli R; Santamato A; Logroscino G
Expert Rev Clin Immunol; 2014 Mar; 10(3):405-19. PubMed ID: 24490853
[TBL] [Abstract][Full Text] [Related]
15. The recent updates of therapeutic approaches against aβ for the treatment of Alzheimer's disease.
Ling S; Zhou J; Rudd JA; Hu Z; Fang M
Anat Rec (Hoboken); 2011 Aug; 294(8):1307-18. PubMed ID: 21717585
[TBL] [Abstract][Full Text] [Related]
16. Anti-Amyloid-β Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise.
van Dyck CH
Biol Psychiatry; 2018 Feb; 83(4):311-319. PubMed ID: 28967385
[TBL] [Abstract][Full Text] [Related]
17. The Role of Amyloid-β Oligomers in Toxicity, Propagation, and Immunotherapy.
Sengupta U; Nilson AN; Kayed R
EBioMedicine; 2016 Apr; 6():42-49. PubMed ID: 27211547
[TBL] [Abstract][Full Text] [Related]
18. Potential treatment opportunities for Alzheimer's disease through inhibition of secretases and Abeta immunization.
Schenk D; Games D; Seubert P
J Mol Neurosci; 2001 Oct; 17(2):259-67. PubMed ID: 11816797
[TBL] [Abstract][Full Text] [Related]
19. [Development of antibodies for immunotherapy of Alzheimer's disease].
Matsumoto SE; Jin H; Takeda K; Hasegawa Y; Motoi Y; Hattori N; Tabira T
Rinsho Shinkeigaku; 2012; 52(11):1168-70. PubMed ID: 23196552
[TBL] [Abstract][Full Text] [Related]
20. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.
Sevigny J; Chiao P; Bussière T; Weinreb PH; Williams L; Maier M; Dunstan R; Salloway S; Chen T; Ling Y; O'Gorman J; Qian F; Arastu M; Li M; Chollate S; Brennan MS; Quintero-Monzon O; Scannevin RH; Arnold HM; Engber T; Rhodes K; Ferrero J; Hang Y; Mikulskis A; Grimm J; Hock C; Nitsch RM; Sandrock A
Nature; 2016 Sep; 537(7618):50-6. PubMed ID: 27582220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
